source
- UniQure shares tumble as Huntington's gene therapy shows reduced benefit over timeUniQure announced new follow-up data from its experimental gene therapy for Huntington's disease, indicating the treatment's effect may diminish with longer observation. The additional year of dat…
- AstraZeneca commits $2 billion to partner Summit Therapeutics on bispecific cancer antibodyAstraZeneca has announced a $2 billion investment to work with Summit Therapeutics. The deal will fund the testing of Summit’s bispecific antibody, ivonescimab, which targets both PD‑1 and VEGF pat…